RE:RE:RE:ONCY Presented Positive GOBLET Pancreatic Cancer Data @ ESMONovember 08, 2024 - Medigene AG, a German immuno-oncology platform company dedicated to developing T cell receptor (TCR)-guided therapies to effectively eliminate cancer, , highlighted recent advances in its proprietary End-to-End Platform to create optimal safe, sensitive, and specific (3S) T cell receptors that can be applied in various modalities, including therapies utilizing T cell receptor engineered T (TCR-T) cells, TCR-guided T cell engagers (TCR-TCEs) and TCR-natural killer cell therapies (TCR-NK) at the Cell 2024 Conference by Oxford Global taking place in London, UK from November 6-8, 2024. https://www.biospace.com/press-releases/medigene-presents-unique-approach-for-use-of-optimal-t-cell-receptors-in-tcr-guided-modalities-at-cell-2024 .......................
ONCY has presented positive data on the use of pelareorep and TCR sequencing in the treatment of breast and pancreatic cancers.
TCR sequencing is a technique that measures the diversity and clonality of T cell receptors (TCRs) in a sample. TCRs are molecules on the surface of T cells that recognize and bind to antigens, which are foreign substances that trigger an immune response. TCR sequencing can provide information about the immune status and activity of a patient, especially in the context of cancer immunotherapy .
TCR sequencing can serve as a surrogate endpoint for clinical trials of cancer immunotherapies, such as checkpoint inhibitors or CAR-T cells. A surrogate endpoint is a measure of effect that can be used instead of a direct measure of clinical benefit, such as survival or quality of life. Surrogate endpoints can help accelerate the development and approval of new therapies, especially for serious or life-threatening conditions .
The rationale for using TCR sequencing as a surrogate endpoint is based on the eidence that TCR diversity and clonality are correlated with the anti-tumor immune response and the clinical outcome of patients. Studies show that higher TCR diversity or clonality in tumor samples or peripheral blood samples are associated with better response rates or survival outcomes in patients treated with immunotherapies .
The validity and reliability of TCR sequencing as a surrogate endpoint is being proven out with pelareorep in the treatment of multiple cancers.